AU2020366300B2 - Methods for treating breast cancer - Google Patents

Methods for treating breast cancer

Info

Publication number
AU2020366300B2
AU2020366300B2 AU2020366300A AU2020366300A AU2020366300B2 AU 2020366300 B2 AU2020366300 B2 AU 2020366300B2 AU 2020366300 A AU2020366300 A AU 2020366300A AU 2020366300 A AU2020366300 A AU 2020366300A AU 2020366300 B2 AU2020366300 B2 AU 2020366300B2
Authority
AU
Australia
Prior art keywords
dapansutrile
breast cancer
tumor
mice
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020366300A
Other languages
English (en)
Other versions
AU2020366300A1 (en
Inventor
Charles A. Dinarello
Isak TENGESDAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics Inc
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Publication of AU2020366300A1 publication Critical patent/AU2020366300A1/en
Assigned to OLATEC THERAPEUTICS, INC. reassignment OLATEC THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: OLATEC THERAPEUTICS LLC
Application granted granted Critical
Publication of AU2020366300B2 publication Critical patent/AU2020366300B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2020366300A 2019-10-14 2020-10-12 Methods for treating breast cancer Active AU2020366300B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914833P 2019-10-14 2019-10-14
US62/914,833 2019-10-14
PCT/US2020/055219 WO2021076444A1 (en) 2019-10-14 2020-10-12 Methods for treating breast cancer

Publications (2)

Publication Number Publication Date
AU2020366300A1 AU2020366300A1 (en) 2022-06-02
AU2020366300B2 true AU2020366300B2 (en) 2026-05-21

Family

ID=75538857

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020366300A Active AU2020366300B2 (en) 2019-10-14 2020-10-12 Methods for treating breast cancer

Country Status (6)

Country Link
US (1) US12582628B2 (cg-RX-API-DMAC10.html)
EP (1) EP4045009A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022551672A (cg-RX-API-DMAC10.html)
CN (1) CN114555053B (cg-RX-API-DMAC10.html)
AU (1) AU2020366300B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021076444A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501657A (ja) * 2022-01-10 2025-01-22 オラテック セラピューティクス， インコーポレイティド 膵臓がんを治療するための方法
EP4487122A4 (en) * 2022-03-02 2026-03-11 Olatec Therapeutics Inc TREATMENT METHODS FOR PATIENTS WITH SOLID CANCER AND CLONAL HEMATOPOIESIS OF UNDETERMINED POTENTIAL
WO2026035767A1 (en) * 2024-08-06 2026-02-12 Olatec Therapeutics, Inc. Methods for treating melanoma metastasis to liver and lungs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182981A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CN104768553A (zh) * 2012-11-02 2015-07-08 默克专利股份公司 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
EP3589370A4 (en) * 2017-01-06 2020-11-18 Olatec Therapeutics LLC MULTIPLE SCLEROSIS TREATMENT METHOD
AU2018313164A1 (en) * 2017-08-11 2020-03-19 Olatec Therapeutics Llc Method for treating Schnitzler's syndrome
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182981A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kaplanov, I. et al., 'Blocking IL -1beta Reverses the Immunosuppression in Mouse Breast Cancer and Synergizes with anti-PD-1 for Tumor Abrogation', Proceedings of the National Academy of Sciences (PNAS). 2019, vol.116, pages 1361-1369 *

Also Published As

Publication number Publication date
EP4045009A4 (en) 2023-11-01
CN114555053A (zh) 2022-05-27
JP2022551672A (ja) 2022-12-12
CN114555053B (zh) 2025-09-30
EP4045009A1 (en) 2022-08-24
WO2021076444A1 (en) 2021-04-22
US20220249425A1 (en) 2022-08-11
AU2020366300A1 (en) 2022-06-02
US12582628B2 (en) 2026-03-24

Similar Documents

Publication Publication Date Title
US12582628B2 (en) Methods for treating breast cancer
US10653669B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
US11857529B2 (en) Methods for treating melanoma
EP4322942A1 (en) Combination comprising everolimus and amcenestrant
US20180243366A1 (en) Drug containing recombinant mistletoe lectins for treating malignant melanoma
EP4338742A1 (en) Application of hydroxyprogesterone caproate in enhancing tumor treatment effect
WO2023245248A1 (en) Treatment of melanoma
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
US20240358669A1 (en) Methods for treating pancreatic cancer
CN113905764A (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法
WO2020026100A1 (en) Combination therapy for treating cancer
CN112533605A (zh) 用于治疗癌症的组合疗法
HK40040830A (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: OLATEC THERAPEUTICS, INC.

Free format text: FORMER NAME(S): OLATEC THERAPEUTICS LLC